Atrial fibrillation: Stroke prevention in focus

被引:16
作者
Ferguson, Caleb [1 ]
Inglis, Sally C. [1 ]
Newton, Phillip J. [1 ]
Middleton, Sandy [2 ,3 ]
Macdonald, Peter S. [3 ,4 ]
Davidson, Patricia M. [1 ,3 ]
机构
[1] Univ Technol Sydney, Fac Hlth, Ctr Cardiovasc & Chron Care, Sydney, NSW 2007, Australia
[2] Australian Catholic Univ, Natl Ctr Clin Outcomes Res NaCCOR, Sydney, NSW, Australia
[3] St Vincents Hosp, Sydney, NSW 2010, Australia
[4] Victor Chang Cardiac Res Inst, Darlinghurst, NSW, Australia
关键词
Atrial fibrillation; Stroke prevention; Clinical management; Anticoagulation; Thromboprophylaxis; Cardiovascular; RISK STRATIFICATION; PREDICTING STROKE; ANTITHROMBOTIC THERAPY; CATHETER ABLATION; HEART-FAILURE; TASK-FORCE; MANAGEMENT; WARFARIN; ANTICOAGULATION; PREVALENCE;
D O I
10.1016/j.aucc.2013.08.002
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Introduction: Atrial fibrillation (AF) is a common arrhythmia and a risk factor for stroke and other, adverse events. Internationally there have been recent advancements in the therapies available for, stroke prevention in AF. Nurses will care for individuals with AF across a variety of primary and acute, care settings and should be familiar with evidence based therapies. Aim: This paper provides a review of the epidemiology of AF and stroke, stroke and bleeding risk, assessment tools and evidence based treatments for the prevention of stroke in AF including the use of, novel anti-thrombin agents. Method: A review of key databases was conducted from 2002 to 2012 using the key search terms 'atrial, fibrillation' anticoagulation' 'riskassessment' and 'clinical management'. The following electronic, databases were searched: CINAHL, Medline, Scopus, the Cochrane Library and Google Scholar., Reference lists were manually hand searched. Key clinical guidelines from National Institute for, Clinical Excellence (NICE, UK), American Heart Association (AHA, USA), American College of Cardiology, (ACC, USA) and the European Society of Cardiology (ESC) and key government policy documents were, also included. Articles were included in the review if they addressed nursing management with a focus, on Australia. Results: Many treatment options exist for AF. Best practice guidelines make a variety of, recommendations which include cardioversion, ablation, pulmonary vein isolation, pharmacological, agents for rate or rhythm control approaches, and antithrombotic therapy (including anticoagulation, and antiplatelet therapy). Treatment should be patient centred and individualised based upon, persistency of the rhythm, causal nature, risk and co-morbid conditions. Conclusion: AF is a common and burdensome condition where treatment is complex and not without, risk. Nurses will encounter individuals with AF across a variety of primary and acute care areas, understanding the risk of AF and appropriate therapies is important across all care settings. Treatment, must be individually tailored to the needs of the patient and balanced with the best available evidence. (C) 2013 Australian College of Critical Care Nurses Ltd. Published by Elsevier Australia (a division of Reed International Books Australia Pty Ltd). All rights reserved.
引用
收藏
页码:92 / 98
页数:7
相关论文
共 85 条
  • [31] ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society
    Fuster, Valentin
    Ryden, Lars E.
    Cannom, David S.
    Crijns, Harry J.
    Curtis, Anne B.
    Ellenbogen, Kenneth A.
    Halperin, Jonathan L.
    Le Heuzey, Jean-Yves
    Kay, G. Neal
    Lowe, James E.
    Olsson, S. Bertil
    Prystowsky, Eric N.
    Tamargo, Juan Luis
    Wann, Samuel
    [J]. CIRCULATION, 2006, 114 (07) : E257 - E354
  • [32] Validation of clinical classification schemes for predicting stroke - Results from the national registry of Atrial Fibrillation
    Gage, BF
    Waterman, AD
    Shannon, W
    Boechler, M
    Rich, MW
    Radford, MJ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (22): : 2864 - 2870
  • [33] Barriers to the use of anticoagulation for nonvalvular atrial fibrillation - A representative survey of Australian family physicians
    Gattellari, Melina
    Worthington, John
    Zwar, Nicholas
    Middleton, Sandy
    [J]. STROKE, 2008, 39 (01) : 227 - 230
  • [34] Outcomes for Patients with Ischaemic Stroke and Atrial Fibrillation: The PRISM Study (A Program of Research Informing Stroke Management)
    Gattellari, Melina
    Goumas, Chris
    Aitken, Robert
    Worthington, John M.
    [J]. CEREBROVASCULAR DISEASES, 2011, 32 (04) : 370 - 382
  • [35] Prevalence of diagnosed atrial fibrillation in adults - National implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study
    Go, AS
    Hylek, EM
    Phillips, KA
    Chang, YC
    Henault, LE
    Selby, JV
    Singer, DE
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (18): : 2370 - 2375
  • [36] Guidelines for the Primary Prevention of Stroke A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association
    Goldstein, Larry B.
    Bushnell, Chair Cheryl D.
    Adams, Robert J.
    Appel, Lawrence J.
    Braun, Lynne T.
    Chaturvedi, Seemant
    Creager, Mark A.
    Culebras, Antonio
    Eckel, Robert H.
    Hart, Robert G.
    Hinchey, Judith A.
    Howard, Virginia J.
    Jauch, Edward C.
    Levine, Steven R.
    Meschia, James F.
    Moore, Wesley S.
    Nixon, J. V.
    Pearson, Thomas A.
    [J]. STROKE, 2011, 42 (02) : 517 - 584
  • [37] Apixaban versus Warfarin in Patients with Atrial Fibrillation
    Granger, Christopher B.
    Alexander, John H.
    McMurray, John J. V.
    Lopes, Renato D.
    Hylek, Elaine M.
    Hanna, Michael
    Al-Khalidi, Hussein R.
    Ansell, Jack
    Atar, Dan
    Avezum, Alvaro
    Cecilia Bahit, M.
    Diaz, Rafael
    Easton, J. Donald
    Ezekowitz, Justin A.
    Flaker, Greg
    Garcia, David
    Geraldes, Margarida
    Gersh, Bernard J.
    Golitsyn, Sergey
    Goto, Shinya
    Hermosillo, Antonio G.
    Hohnloser, Stefan H.
    Horowitz, John
    Mohan, Puneet
    Jansky, Petr
    Lewis, Basil S.
    Luis Lopez-Sendon, Jose
    Pais, Prem
    Parkhomenko, Alexander
    Verheugt, Freek W. A.
    Zhu, Jun
    Wallentin, Lars
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (11) : 981 - 992
  • [38] Hall BW, 2002, J AM COLL CARDIOL, V39, p89A
  • [39] Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk - The atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W)
    Healey, Jeff S.
    Hart, Robert G.
    Pogue, Janice
    Pfeffer, Marc A.
    Hohnloser, Stefan H.
    De Caterina, Raffaele
    Flaker, Greg
    Yusuf, Salim
    Connolly, Stuart J.
    [J]. STROKE, 2008, 39 (05) : 1482 - 1486
  • [40] Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial
    Holmes, David R.
    Reddy, Vivek Y.
    Turi, Zoltan G.
    Doshi, Shephal K.
    Sievert, Horst
    Buchbinder, Maurice
    Mullin, Christopher M.
    Sick, Peter
    [J]. LANCET, 2009, 374 (9689) : 534 - 542